Why Korsana Biosciences, Inc.’s (KRSA) Stock Is Down 7.63%
As of Wednesday, September 30, Korsana Biosciences, Inc.’s KRSA share price has dipped by 7.63%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
Commentary & Analysis
Why Korsana Biosciences, Inc.’s (KRSA) Stock Is Up 5.32%
As of Tuesday, September 29, Korsana Biosciences, Inc.’s KRSA share price has surged by 5.32%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Korsana Biosciences, Inc.’s (KRSA) Stock Is Up 6.16%
As of Monday, September 28, Korsana Biosciences, Inc.’s KRSA share price has surged by 6.16%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Korsana Biosciences, Inc.’s (KRSA) Stock Is Down 10.64%
As of Friday, September 25, Korsana Biosciences, Inc.’s KRSA share price has dipped by 10.64%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Korsana Biosciences, Inc.’s (KRSA) Stock Is Down 11.07%
As of Friday, September 25, Korsana Biosciences, Inc.’s KRSA share price has dipped by 11.07%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | KRSA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,474.6 | $208.8 | 51% |
|
| Shares Out (Mil) | 5.0 | 53.9 | 14% |
|
| Institutional Ownership | 98.0% | 93.1% | 76% |
|
| Float (Mil) | 32.7 | 41.4 | 38% |
|
| Beta | 1.73 | 0.95 | 87% |
|
| Avg Daily Volume (000s) | 114 | 614 | 38% |
|
| Price Change (52-week) |
95.2% | 45.3% | 94% |
|
| Growth | KRSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.2%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | KRSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($49) | ($44) | 16% |
|
| EPS (TTM) | ($13.371) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($42) | ($33) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | $1,442 | $174 | 45% |
|
| Valuation | KRSA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.09 | na |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | KRSA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (71.3%) | (47.2%) | 8% |
|
| ROE | 208.7% | (54.2%) | 98% |
|
| Liabilities to Assets | 6.7% | 29.1% | 3% |
|
| F-Score | 1 | 2 | na |
|
Korsana Biosciences, Inc. did not pass any screens on 10/16/2026.
